Study to Eliminate Hib Carriage in Rural Alaska Native Villages
NCT00153556
Completed
Hib disease rates in rural Alaska before introduction of HIb conjugate vaccine were among the highest in the world. Since vaccine introduction, rates have fallen by 90% but the disease has not been eliminated. This study is designed to test one possible means of eliminating Hib carriage and thus to eliminate person to person transmission and invasive disease. The objective of this study is to evaluate the effectiveness of community-wide use of Hib conjugate vaccine for eliminating oropharyngeal... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
09/08/2005
Locations: CDC Arctic Investigations Program, Anchorage, Alaska
Conditions: Haemophilus Influenzae Type B, Carrier State
Register for Updates
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
NCT00002428
Completed
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in alum for intramuscular administration in intermediate or higher risk HIV-negative volunteers.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/23/2005
Locations: Univ of California at San Francisco Gen Hosp, San Francisco, California
Conditions: HIV Infections
Register for Updates